Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 1/20 | 0.40 |
| ▸ | PLAT | P00750 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.39 |
| ▸ | GABRE | P78334 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.39 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.39 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3278388 | 1.00 | PLG (0.40) | PLGPLATLMNATSHRGABRP | |
| SCHEMBL3997323 | 1.00 | PLG (0.40) | PLGPLATLMNATSHRGABRP | |
| SCHEMBL6509408 | 0.92 | PLG (0.35) | PLGPLATLMNATSHRGABRP | |
| SCHEMBL19431348 | 0.92 | PLG (0.35) | PLGPLATLMNATSHRGABRP | |
| SCHEMBL19431480 | 0.92 | PLG (0.35) | PLGPLATLMNATSHRGABRP | |
| SCHEMBL19431487 | 0.92 | PLG (0.35) | PLGPLATLMNATSHRGABRP | |
| SCHEMBL19431406 | 0.92 | PLG (0.35) | PLGPLATLMNATSHRGABRP | |
| SCHEMBL177205 | 0.85 | — | — | |
| SCHEMBL12476221 | 0.85 | CHRM2 (0.42) | LMNATSHRCHRM2CHRM1CHRM4 | |
| SCHEMBL19431471 | 0.84 | SCN1A (0.48) | LMNATSHRMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022116-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI-AVENTIS RECHERCHE & DÉVELOPPEMENT (FR) | 2026-01-22 | — | — | US | disclosed |
| EP-4558500-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | Sanofi (FR) | 2025-05-28 | — | — | EP | disclosed |
| WO-2024017977-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024017977-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2024-01-25 | — | — | WO | disclosed |
| US-20230331738-A1 | ANTI-TUMOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | DUALITY BIOLOGICS (SUZHOU) CO., LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230331738-A1 | ANTI-TUMOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | DUALITY BIOLOGICS (SUZHOU) CO., LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| EP-4223318-A1 | ANTITUMOR COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Duality Biologics (Suzhou) Co., Ltd. (CN) | 2023-08-09 | — | — | EP | disclosed |
| US-20230212182-A1 | ANTI-TUMOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | DUALITY BIOLOGICS (SUZHOU) CO., LTD. (CN) | 2023-07-06 | — | — | US | disclosed |
| US-20230212182-A1 | ANTI-TUMOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | DUALITY BIOLOGICS (SUZHOU) CO., LTD. (CN) | 2023-07-06 | — | — | US | disclosed |
| US-11685742-B2 | Anti-tumor compound and preparation method and use thereof | DUALITY BIOLOGICS (SUZHOU) CO., LTD. (CN) | 2023-06-27 | — | — | US | disclosed |
| US-20140315790-A1 | AMINOTHIAZOLES AND THEIR USES | BUSHELL SIMON (US) | 2014-10-23 | — | — | US | disclosed |
| EP-2044101-B1 | AMINOTHIAZOLE DERIVATIVES AND THEIR USES AS ANTIBACTERIAL AGENTS | NOVARTIS AG (CH) | 2013-10-09 | — | — | EP | disclosed |
| US-20090286790-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-11-19 | — | — | US | disclosed |
| US-20090286790-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-11-19 | — | — | US | disclosed |
| WO-2008009435-A1 | AMINO-PIPERIDINE DERIVATIVES AS CETP INHIBITORS | NOVARTIS AG (CH) | 2008-01-24 | — | — | WO | disclosed |
| EP-0993459-B1 | COMPOUNDS USEFUL FOR INHIBITION OF FARNESYL PROTEIN TRANSFERASE | SCHERING CORP (US) | 2002-11-06 | — | — | EP | disclosed |
| US-6410541-B2 | BENZO(5,6)CYCLOHEPTA(1,2-B)PYRIDINE DERIVATIVES ADMINISTERED AS ANTITUMOR AGENTS | SCHERING CORPORATION | 2002-06-25 | — | — | US | disclosed |
| US-6211193-B1 | BENZO(5,6)CYCLOHEPTA(1,2-B)PYRIDINE DERIVATIVES; ANTITUMOR AND ANTICARCINOGENIC AGENTS | SCHERING CORPORATION | 2001-04-03 | — | — | US | disclosed |
| EP-0993459-A1 | COMPOUNDS USEFUL FOR INHIBITION OF FARNESYL PROTEIN TRANSFERASE | SCHERING CORPORATION (US) | 2000-04-19 | — | — | EP | disclosed |
| WO-1998057955-A1 | COMPOUNDS USEFUL FOR INHIBITION OF FARNESYL PROTEIN TRANSFERASE | SCHERING CORPORATION (US) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286790-A1 | ORGANIC COMPOUNDS | CETP, NPC1, CES1 | PLG 3175/4885PLAT 2736/4885LMNA 1536/4885 |
| US-20230212182-A1 | ANTI-TUMOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | RCC2, REN, VHL | PLG 1360/4885PLAT 1743/4885LMNA 1004/4885 |
| US-20230331738-A1 | ANTI-TUMOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | RCC2, REN, VHL | PLG 1360/4885PLAT 1743/4885LMNA 1004/4885 |
| US-11685742-B2 | Anti-tumor compound and preparation method and use thereof | RCC2, REN, VHL | PLG 1360/4885PLAT 1743/4885LMNA 1004/4885 |
| US-20140315790-A1 | AMINOTHIAZOLES AND THEIR USES | ABAT, AADAT, GOT2 | PLG 2052/4885PLAT 2948/4885LMNA 2527/4885 |
| US-20260022116-A1 | IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | MAPK1, MAPK3, MAPK6 | PLG 4655/4885PLAT 4825/4885LMNA 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.